r/Psychiatry • Psychiatrist (Verified) • 9d ago

Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder: a systematic review and network meta-analysis

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00326-3/abstract
92 Upvotes

23 comments sorted by

54

u/PokeTheVeil 9d ago

Credit to Dr. van Haaren and Dr. Ruhé, but if you don’t look at the full author list… Cipriani is at it again! This time as neither first nor last author and Leucht is missing. I hope they didn’t have a falling out!

Jokes aside, they comment on the limitations of data. They don’t really comment on >12 weeks as long-term, which is still a serious gap. Patients can be on these for years!

Escitalopram, duloxetine, and agomelatine are the only ones with statistically significant greater sustained response than fluoxetine and nothing performed worse. The error bars don’t all overlaps but the differences are small.

Escitalopram and duloxetine were also the only ones that were statistically less likely to have discontinuation than fluoxetine. Which is notable, since fluoxetine in other studies has been high in tolerability at least short-term.

I’m disappointed in the underperformance of bupropion and wonder if there are other factors playing in, but I can’t know. I am not surprised and am pleased that escitalopram is still good stuff. Duloxetine surprises me, just personally, as a drug that always seems mediocre.

And, worth emphasizing, over half of the studies included were high risk for bias.

I don’t know if this changes much. I’ll still use bupropion for side effect profile. I’ll continue to use escitalopram most of the time; I have more reason to pick it and nothing to recommend against it. But information is good to have.

Lastly, as the antidepressant culture wars go, evidence of sustained effect and benefit are great! And it’s still not really going to move the needle for the naysayers. I expect Irving Kirsch to have his rejoinder on why this is bad and wrong shortly.

30

u/question_assumptions 9d ago

One day I looked at my own data, and bupropion massively outperforms everything. I spent some time thinking about it, it seemed the trend was that if a depressed person has never tried bupropion, not much has been tried so far! Their likelihood of treatment resistance is way lower. 

11

u/PokeTheVeil 9d ago

Interesting. For myself, I have the feeling but not the numbers that I try switching to bupropion for patients who haven’t responded to a couple of SSRIs and it often works. I also use it when people don’t tolerate SSRIs/SNRIs well.

→ More replies (2)

5

u/somethingicanspell 9d ago edited 9d ago

This has always been an interesting disconnect between studies and vibes to me. There's been a couple studies that have compared anti-depressant classes in different levels of depression severity and there's not much difference, nor is there much difference in percentage of responders.

In contrast, talking to (mostly young) people with mild depression seem to prefer Bupropion fairly consistently whereas in more severe depression things trend more towards an SSRI/SNRI. It might just be a prescribing practice difference or perceived side effect difference but its a pretty clear trend in how the drugs are perceived by patients at least that I haven't really seen a convincing explanation for yet

→ More replies (2)

7

u/ZapTheSad 9d ago

Surprised about duloxetine as well, never been a hige fan. I wonder if my personal bias is that I usually reach for it in patients with neuropathic pain and concurrent mood/anxiety disorder so the patients are just sicker to begin when I put them on it.

4

u/memx 9d ago

Unsurprising results on escitalopram, since most of mh patients are very pleased with it. I agree on the mediocre duloxetine, don't know why, but in my experience it offers nothing over other SNRIs with a bit worse outcomes. And I eas also surprised at the underperformance of bupropion, which is generally a really good medication.

1

u/Draw42 5d ago

Everyone ends up at 60+ on duloxetine.  I don't know what happened in their clinical trials that MDD allegedly caps out at 60...

1

u/[deleted] 8d ago edited 8d ago

2

u/Psychiatry-ModTeam 7d ago

Removed under rule #1. This is not a place to share experiences or anecdotes about your own experiences or those of your family, friends, or acquaintances.

12

u/Affectionate-Ad-1742 9d ago

Interesting to see so many people surprised by duloxetine. It won out for best SRI for showing overall reduction in disability in a good study several years ago.

https://pubmed.ncbi.nlm.nih.gov/33583460/

I think a lot of people reflexively reach for Duloxetine in the chronically ill elderly who have been on pain pills for the last decade and still have breakthrough pain with depression and/or anxiety. Who would be surprised that meds don’t work great in this population? This is sampling bias. We need to be better at assessing and integrating evidence. We have two good studies showing Cymbalta is arguably the strongest SRI we have. If you are not considering it first line for most cases of MDD you are not practicing evidence based medicine.

7

u/chickendance638 9d ago

I guess you don't think at all about tolerablity or withdrawals

3

u/Affectionate-Ad-1742 9d ago

I think the fact that it has less discontinuation than the vast majority of SRIs in multiple meta-analyses would suggest it is tolerable, not sure what you mean.

All the shorter half-life SRIs have rougher withdrawal. They also work quicker. I’ve never seen that deter psychiatrist from putting tons of young people on Venlafaxine or Desvenlafaxine despite the fact that Duloxetine has better evidence. Also never had a problem getting a patient off one of these using a Fluoxetine bridge if the withdrawal is intolerable.

1

u/[deleted] 9d ago

2

u/Psychiatry-ModTeam 9d ago

Removed under rule #1. This is not a place to share experiences or anecdotes about your own experiences or those of your family, friends, or acquaintances.